The Office of Regulatory Policy sits within the FDA’s Center for Drug Evaluation and Research. In her role, Ms. Jungman will oversee drug safety policies. She has worked closely with the FDA in her role at Pew and has vocally supported some of the FDA’s more controversial policies, such as stricter standards for drug compounding.
Ms. Jungman also was a senior health policy adviser for the Democratic majority on the Senate Health, Education, Labor and Pensions Committee for two years.
